Type I interferon pathway activation in COPA syndrome

Copyright © 2017. Published by Elsevier Inc.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 187(2018) vom: 20. Feb., Seite 33-36
1. Verfasser: Volpi, Stefano (VerfasserIn)
Weitere Verfasser: Tsui, Jessica, Mariani, Marcello, Pastorino, Claudia, Caorsi, Roberta, Sacco, Oliviero, Ravelli, Angelo, Shum, Anthony K, Gattorno, Marco, Picco, Paolo
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2018
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Case Reports Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Autoinflammatory diseases COPA syndrome Type 1 interferonopathy Antibodies, Antinuclear Coatomer Protein Interferon Type I mehr... Rheumatoid Factor 9009-79-4
LEADER 01000naa a22002652 4500
001 NLM27699096X
003 DE-627
005 20231225013217.0
007 cr uuu---uuuuu
008 231225s2018 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.clim.2017.10.001  |2 doi 
028 5 2 |a pubmed24n0923.xml 
035 |a (DE-627)NLM27699096X 
035 |a (NLM)29030294 
035 |a (PII)S1521-6616(17)30688-5 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Volpi, Stefano  |e verfasserin  |4 aut 
245 1 0 |a Type I interferon pathway activation in COPA syndrome 
264 1 |c 2018 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 18.03.2019 
500 |a Date Revised 21.01.2021 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a Copyright © 2017. Published by Elsevier Inc. 
520 |a Mutations of the COPA gene cause an immune dysregulatory disease characterised by polyarticular arthritis and progressive interstitial lung disease with pulmonary haemorrhages. We report the case of a young girl that presented at age 3 with polyarticular arthritis, chronic cough and high titer rheumatoid factor. Radiologic imaging showed interstitial lung disease with tree-in-a-bud nodules and air-filled cysts. Targeted genetic analysis of COPA gene showed the reported c.698G>A mutation. The patient was lost to follow up for 3years during which therapy was discontinued with the development of joint damage and deformities. Analysis of peripheral blood showed activation of type 1 interferon pathway, which was also confirmed in 4 previously reported COPA patients. Our observations underline the importance of early treatment in COPA disease to avoid loss of joint function. Furthermore, our results suggest a role for type 1 interferon in disease pathogenesis opening the possibility for targeted therapeutic approaches 
650 4 |a Case Reports 
650 4 |a Journal Article 
650 4 |a Research Support, N.I.H., Extramural 
650 4 |a Research Support, Non-U.S. Gov't 
650 4 |a Autoinflammatory diseases 
650 4 |a COPA syndrome 
650 4 |a Type 1 interferonopathy 
650 7 |a Antibodies, Antinuclear  |2 NLM 
650 7 |a Coatomer Protein  |2 NLM 
650 7 |a Interferon Type I  |2 NLM 
650 7 |a Rheumatoid Factor  |2 NLM 
650 7 |a 9009-79-4  |2 NLM 
700 1 |a Tsui, Jessica  |e verfasserin  |4 aut 
700 1 |a Mariani, Marcello  |e verfasserin  |4 aut 
700 1 |a Pastorino, Claudia  |e verfasserin  |4 aut 
700 1 |a Caorsi, Roberta  |e verfasserin  |4 aut 
700 1 |a Sacco, Oliviero  |e verfasserin  |4 aut 
700 1 |a Ravelli, Angelo  |e verfasserin  |4 aut 
700 1 |a Shum, Anthony K  |e verfasserin  |4 aut 
700 1 |a Gattorno, Marco  |e verfasserin  |4 aut 
700 1 |a Picco, Paolo  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Clinical immunology (Orlando, Fla.)  |d 1999  |g 187(2018) vom: 20. Feb., Seite 33-36  |w (DE-627)NLM098196855  |x 1521-7035  |7 nnns 
773 1 8 |g volume:187  |g year:2018  |g day:20  |g month:02  |g pages:33-36 
856 4 0 |u http://dx.doi.org/10.1016/j.clim.2017.10.001  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 187  |j 2018  |b 20  |c 02  |h 33-36